EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Recruiting · NCT05467748 · Registry updated 2026-01-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-01-27 | NCT05467748 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| VA Greater Los Angeles Healthcare System | 15 |
| VA Office of Research and Development | 472 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Michael E. DeBakey VA Medical Center, Houston, TX | Houston | United States | 30 |
| VA Ann Arbor Healthcare System, Ann Arbor, MI | Ann Arbor | United States | 24 |
| VA Long Beach Healthcare System, Long Beach, CA | Long Beach | United States | 22 |
| VA Northern California Health Care System, Mather, CA | Sacramento | United States | 6 |
| VA San Diego Healthcare System, San Diego, CA | San Diego | United States | 37 |